The President and Chief Executive Officer of Opexa Therapeutics, Neil K. Warma, was recently invited to host a presentation at the Cleveland Clinic’s 12th Annual Medical Innovation Summit, which will take place between October 26 and 29 in Cleveland, Ohio. Opexa is a Woodlands, TX – based company currently developing personalized immunotherapies for the treatment of autoimmune diseases like multiple sclerosis (MS) and Neuromyelitis Optica (NMO).
Opexa’s presentation will be included in the Ground Waves showcase, and will take place next Wednesday, October 29, at 9:15 am ET at the Cleveland Convention Center. The showcase will last two days and is part of the summit, in which several companies will present their latest products and initiatives both in personalized medicine and the treatment of cancer — the two main focuses of the 12th Annual Medical Innovation Summit.
The organizers of “Now, it’s Personal” believe that more than 1,500 people will attend the event, including executives, investors, entrepreneurs and clinicians, to discuss innovations on the two topics. The Cleveland Clinic announced the anticipated attendance of healthcare stakeholders from pharmaceutical companies, diagnostic developers, and medical device companies in order to advance the discussion on targeted and personalized therapies.
Mr. Warma will be representing Opexa’s experimental therapeutics, which work based mainly on their proprietary T-cell technology. Tcelna is the company’s lead therapeutic candidate, and is now in the phase IIb clinical development stage of the “Abili-T” study, after recently finishing enrolling 180 patients suffering from progressive multiple sclerosis in 35 clinical sites in the United States and Canada.
Spreading the company’s mission of leading the field of Precision Immunotherapy, Warma has made appearances at several recent high-profile events. Most recently, the CEO was invited to present at the Rodman & Renshaw 16th Annual Healthcare Conference, which took place in New York, and at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, in Las Vegas, Nevada, both of which took place in September.
In addition to Tcelna, Opexa has recently announced the expansion of its intellectual property portfolio, as they are now seeking to enlarge their IP protection to cover B-cell mediated diseases as part of their launch of a new development program for Neuromyelitis Optica. The company’s property portfolio includes 98 issued and validated patents throughout the world.